2 recruiting, 1 completed. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Completed 1 |
| Phase 1 | 2 | Recruiting 2 |
Follow Plasma Cell Disorder: new trials by email Literature Review of Plasma Cell Disorder trials Research Report on Plasma Cell Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders Daratumumab Injection - Plasma Cell Disorder | Phase 1 / Phase 2 | Recruiting | University of Maryland, Baltimore | 30 | 2025-10-23 | 2026-10-29 |
| Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma HDP-101 - Multiple Myeloma, Plasma Cell Disorder | Phase 1 / Phase 2 | Recruiting | Heidelberg Pharma AG | 78 | 2022-02-07 | 2026-09-17 |
| Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias Lenalidomide, Placebo - Plasma Cell Disorder | Phase 2 | Completed | Boston VA Research Institute, Inc. | 38 | 2005-04-01 | 2016-05-17 |
Neoplasms, Plasma Cell (3) · Multiple Myeloma (1)
Neoplasms (3) · Neoplasms by Histologic Type (3) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphoproliferative Disorders (1) · Paraproteinemias (1) · Vascular Diseases (1)
Lenalidomide (1) · Sugars (1) · daratumumab (1)
Boston VA Research Institute, Inc. (1) · Heidelberg Pharma AG (1) · University of Maryland, Baltimore (1)
United States (3) · Germany (1) · Hungary (1) · Poland (1) · Romania (1)
Ashraf Badros, MD (1) · Nikhil C Munshi, M.D. (1)